Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus - defining adequate administration methods

Table 15 Change in HbA1c % before and after autologous bone marrow derived stem cell therapy in Group III

Patient	Baseline	3 mo	6 mo	12 mo	18 mo
1	6.3	6.2	5.9	7.1	5.9
2	6.8	5.8	6.8	6.3	-
3	6.9	6.9	6.9	7.4	-
4	6.8	6.7	7.2	7	-
5	6.9	7.2	7.5	7.5	-
6	6	6	6.2	-	-
7	7.2	6.8	6.4	-	-
Mean ± SE	6.7 ± 0.15	6.5 ± 0.19	6.7 ± 0.21
P value		0.28	0.999